D'AVOLIO, Antonio

D'AVOLIO, Antonio  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 168 (tempo di esecuzione: 0.027 secondi).
Titolo Data di pubblicazione Autore(i) File
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 2014 A. De Nicolò; A. Ciancio; L. Boglione; A. Mohamed Abdi; A. Smedile; G.P. Caviglia; G. DI Perri; M. Rizzetto; A. D'Avolio
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 2010 Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G.
A new HPLC method to measure plasma levels of enfuvirtide (ENF or T-20) 2004 D'Avolio A.; Sciandra M.; Bonora S.; Ibanez A.; Marucco D.; Di Perri G.
A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD) 2015 L. Baietto; V. Poretti; K. Baruffi; G. Di Perri; A. D'Avolio
A new validated Solid Phase Extraction (SPE)-HPLC method to measure plasma concentrations of tenofovir 2004 D'Avolio A.; Sciandra M.; Bonora S.; Boffito M.; Canta F.; De Requena D.; Di Perri G.
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 2008 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 2009 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance 2010 Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 2016 D'Avolio, A.; Ariaudo, A.; Favata, F.; De Nicolò, A.; Simiele, M.; Boglione, L.; Carcieri, C.; Di Perri, G.
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 2016 Pensi, D.; De Nicolò, A.; Favata, F.; Pisciotta, C.; Di Perri, G.; D'Avolio, A.
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 2009 Antonio D'Avolio; Marco Siccardi; Deborah Gatti; Lorena Baietto; Francesca Romana Stefani; Marco Simiele; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 2014 Pensi D; De Nicolò A; Pinon M; Calvo PL; Di Perri G; D'Avolio A
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 2010 Bonora S; Calcagno A; Viganò O; Bigliano P; Rusconi S; Trentini L; Tettoni MC; Orofino G; Salassa B; Bramato C; D'Avolio A; Siccardi M; Colella E; Galli M; Di Perri G
Anidulafungin pharmacokinetic evaluation in a cohort of patients 2011 F.G. De Rosa; L. Baietto; A. D’Avolio; D. Pasero; S. Raviolo; S. Pace; C. Marra; V.M. Ranieri; G. Di Perri
Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, fluoroquinolones and carbapenems 2007 S. Garazzino; A. Aprato; D. Aloj; F.G. De Rosa; A. D'Avolio; A. Massé; G. Di Perri
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 2017 De Nicolò, A.; Boglione, L.; Carcieri, C.; Cusato, J.; Mornese Pinna, S.; Favata, F.; Ariaudo, A.; Di Perri, G.; D’Avolio, A.
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 2010 Marco Simiele; Antonio D’Avolio; Marco Siccardi; Lorena Baietto; Francesca Romana Stefani; Silvia Agati; Jessica Cusato; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri
ASSORBENTI IGIENICI: SINTOMATOLOGIA ED ISOLAMENTI MICROBIOLOGICI 2003 Audisio G.; Amarù G.; D'Avolio A.; Orso Giacone G.; Properzi C.
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study 2012 Brizzi MP; Fazio N; Ferrero A; Nobili E; Volante M; Tozzi L; D'Avolio A; Milanesi E; Dogliotti L; Berruti A
Calcyclin, b-actin and H3-histone expression is modulated by sex steroids in hormone dependent human mammary cells (CG5) 1996 GHEZZO F; G. BERTA; D'AVOLIO A; RACCA S; CONTI G; DI CARLO F